About Stellence Pharmscience Private Limited
Data last updated:
Stellence Pharmscience Private Limited is a private limited company based in Bangalore, Karnataka, India, a subsidiary of Avigna Chemitech Private Limited. The company is currently undergoing Corporate Insolvency Resolution Process (CIRP) under the Insolvency and Bankruptcy Code, 2016. Management control has been transferred to an insolvency professional. It operates in the API manufacturers segment of the pharmaceuticals sector. It was incorporated on 01 January 1992.
The company is registered with the Registrar of Companies (ROC), Bangalore, under CIN U85110KA1992PTC012673. Its GSTIN is 29AABCK9903A1ZP (Karnataka).
The company has an authorised share capital of ₹85 Cr and a paid-up capital of ₹43 Cr. It was formerly known as Karnataka Chemsyn Limited and Stellence Pharmscience Limited. It is led by directors including Ramachandran Radhakrishnan (Managing Director) and Naveen Kumar Jain (Irp/Rp/Liquidator).
Its last annual general meeting (AGM) was held on 30 September 2022, and its latest financial statements are for the year ended 31 March 2022. The registered office is at No.456 1A And 1B Industrial Area Jigani, Bangalore, Karnataka, India – 562106.
As per the financials filed for FY 2022, the company reported a revenue of ₹29.16 Cr, a decline of 16% compared to the previous year. For the same year it recorded a net loss of ₹5.88 Cr (net margin -20.2%) and EBITDA of ₹4.48 Cr (EBITDA margin 15.4%). Revenue has declined at a compounded annual rate (CAGR) of 23% over three years and 8% over five years.
The company has about 103 employees on its provident fund (EPFO) records.
The company is associated with 2 brands: Stellence Pharmscience and Avigna Pharmaceuticals. As per MCA filings, the company has open charges of ₹38 Cr and satisfied charges of ₹31.92 Cr on record. Court records list 23 cases involving the company, including 8 filed by the company and 15 filed against it; 8 cases are pending.
The last known website on record is stellencepharmscience.com.
- EmailLocked
- TelephoneLocked
- Website
- Social MediaLocked
- Registered AddressNo.456 1A And 1B Industrial Area Jigani, Bangalore, Karnataka, India – 562106
- IndustryPharma, API Manufacturers
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Business Activity of Stellence Pharmscience Private Limited
The main business activity of Stellence Pharmscience is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | Locked |
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Financials of Stellence Pharmscience Private Limited FY 2022 filings available
Stellence Pharmscience Private Limited reported revenue of ₹29.16 Cr (down 16% YoY) for FY 2022.
Compounded Annual Growth Rate (CAGR) of Stellence Pharmscience Private Limited
Revenue has declined at a compounded annual rate (CAGR) of 8% over five years, including a 16% fall in the latest year. EBITDA fell 53% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary of Stellence Pharmscience Private Limited
| Metrics | FY 2021-22 | FY 2020-21 | FY 2019-20 | FY 2018-19 | FY 2017-18 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | •••• | •••• | •••• | •••• | •••• |
| Other Income | •••• | •••• | •••• | •••• | •••• |
| Total Revenue | ₹29.16 Cr | •••• | •••• | •••• | •••• |
| Cost of Materials Consumed | •••• | •••• | •••• | •••• | •••• |
| Employee Benefit Expense | •••• | •••• | •••• | •••• | •••• |
| Finance Costs | •••• | •••• | •••• | •••• | •••• |
| Depreciation and Amortisation | •••• | •••• | •••• | •••• | •••• |
| Other Expenses | •••• | •••• | •••• | •••• | •••• |
| Total Expenses | •••• | •••• | •••• | •••• | •••• |
| EBITDA | ₹4.48 Cr | •••• | •••• | •••• | •••• |
| Profit Before Tax | •••• | •••• | •••• | •••• | •••• |
| Tax Expense | •••• | •••• | •••• | •••• | •••• |
| Net Profit (PAT) | -₹5.88 Cr | •••• | •••• | •••• | •••• |
| Balance Sheet | |||||
| Share Capital | •••• | •••• | •••• | •••• | •••• |
| Reserves and Surplus | •••• | •••• | •••• | •••• | •••• |
| Net Worth (Total Equity) | •••• | •••• | •••• | •••• | •••• |
| Long-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Short-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Trade Payables | •••• | •••• | •••• | •••• | •••• |
| Total Liabilities | •••• | •••• | •••• | •••• | •••• |
| Fixed Assets | •••• | •••• | •••• | •••• | •••• |
| Investments | •••• | •••• | •••• | •••• | •••• |
| Inventories | •••• | •••• | •••• | •••• | •••• |
| Trade Receivables | •••• | •••• | •••• | •••• | •••• |
| Cash and Bank Balance | •••• | •••• | •••• | •••• | •••• |
| Total Assets | •••• | •••• | •••• | •••• | •••• |
Financial Ratios of Stellence Pharmscience Private Limited
| Metrics | FY 2021-22 | FY 2020-21 | FY 2019-20 | FY 2018-19 | FY 2017-18 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 15.4% | •••• | •••• | •••• | •••• |
| Net Profit Margin | -20.2% | •••• | •••• | •••• | •••• |
| Return on Equity (ROE) | •••• | •••• | •••• | •••• | •••• |
| Return on Capital Employed (ROCE) | •••• | •••• | •••• | •••• | •••• |
| Return on Assets (ROA) | •••• | •••• | •••• | •••• | •••• |
| Liquidity and Debt | |||||
| Current Ratio | •••• | •••• | •••• | •••• | •••• |
| Quick Ratio | •••• | •••• | •••• | •••• | •••• |
| Debt-to-Equity Ratio | •••• | •••• | •••• | •••• | •••• |
| Interest Coverage Ratio | •••• | •••• | •••• | •••• | •••• |
| Efficiency and Growth | |||||
| Asset Turnover | •••• | •••• | •••• | •••• | •••• |
| Receivable Days | •••• | •••• | •••• | •••• | •••• |
| Payable Days | •••• | •••• | •••• | •••• | •••• |
| Inventory Days | •••• | •••• | •••• | •••• | •••• |
| Revenue Growth | •••• | •••• | •••• | •••• | •••• |
| Net Profit Growth | •••• | •••• | •••• | •••• | •••• |
Paid data: the figures shown as dots are available after purchase of the company report. Figures as filed with the MCA in Form AOC-4. The full year-wise statements and ratios of Stellence Pharmscience are in the company report.
Financial statements from 2015
Earlier years and trend charts are in the company report.
- Income statements
- Balance sheets
- Cash-flow statements
- Ratios and benchmarks
Verified entity values are shown only after access is granted.
Peer Comparison of Stellence Pharmscience Private Limited
Stellence Pharmscience Private Limited is compared with the companies closest to it by revenue in the Pharma industry (API Manufacturers). Net profit, margin and employee counts of each company are in the company report.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Magnum Chemi-Gran Private Limited | ₹29.74 Cr (FY 2025) | •••• | •••• | 38.0% | •••• | Hyderabad, Telangana, India |
| Mahrshee Organics Private Limited | ₹29.58 Cr (FY 2025) | •••• | •••• | 0.0% | •••• | Panoli, Gujarat, India |
| Admiron Life Sciences Private Limited | ₹29.41 Cr (FY 2024) | •••• | •••• | -43.0% | •••• | Hyderabad, Telangana, India |
| G.M. Chemie Private Limited | ₹29.36 Cr (FY 2025) | •••• | •••• | 43.0% | •••• | Navi Mumbai, Maharashtra, India |
| Trimax Bio Sciences Private Limited | ₹29.26 Cr (FY 2025) | •••• | •••• | -49.0% | •••• | Hyderabad, Telangana, India |
| Stellence Pharmscience Private Limited this company | ₹29.16 Cr (FY 2022) | •••• | •••• | -16.0% | •••• | Bangalore, Karnataka, India |
| Sri Haas Life Sciences Private Limited | ₹28.99 Cr (FY 2025) | •••• | •••• | 60.0% | •••• | Hyderabad, Telangana, India |
| Asg Biochem Private Limited | ₹28.92 Cr (FY 2025) | •••• | •••• | -9.0% | •••• | New Delhi, Delhi, India |
| Livmore Life Sciences Private Limited | ₹28.89 Cr (FY 2025) | •••• | •••• | 296.0% | •••• | Vadodara, Gujarat, India |
| Surya Remedies Private Limited | ₹28.86 Cr (FY 2024) | •••• | •••• | 9.0% | •••• | Ankleshwar, Gujarat, India |
| Pranami Drugs Private Limited | ₹28.27 Cr (FY 2025) | •••• | •••• | 17.0% | •••• | Ankleshwar, Gujarat, India |
Peers are the five companies nearest above and the five nearest below Stellence Pharmscience by revenue in the Pharma industry (API Manufacturers), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.
Auditor Details of Stellence Pharmscience Private Limited
Stellence Pharmscience Private Limited is audited by P CHANDRASEKAR LLP for the financial year 2022.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| P CHANDRASEKAR LLP | Locked | Locked | Locked |
Complete auditor history
Appointment and cessation dates and past auditor changes are in the company report.
- Appointment status
- Appointment dates
- Cessation dates
- Auditor changes
Verified entity values are shown only after access is granted.
Board of Directors of Stellence Pharmscience Private Limited
Stellence Pharmscience has 5 current directors and 9 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Naveen Kumar Jain Also directs: Smartnomics Advisors LLP | Irp/Rp/Liquidator | 16 Jul 2024 | 2 Years 2 Months | As last reported |
| Ramachandran Radhakrishnan | Managing Director | 23 Aug 2006 | 20 Years 1 Months | As last reported |
| Anuradha Ramachandran | Director | 15 May 2019 | 7 Years 5 Months | As last reported |
| Akash Mathur | Director | 01 Apr 2020 | 6 Years 6 Months | As last reported |
| Lalit Kumar Yadav | Director | 01 Apr 2020 | 6 Years 6 Months | As last reported |
Ownership and Shareholding of Stellence Pharmscience Private Limited
Shareholding and ownership data
Promoter, institutional, public and beneficial ownership figures are in the company report.
- Ownership categories
- Historical changes
- Group structure
- FII and DII holdings
Verified entity values are shown only after access is granted.
Charges & Borrowings of Stellence Pharmscience Private Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 30 Jun 2017 | Tata Capital Financial Services Limited | ₹7.5 Cr | Open |
| 28 Jul 2015 | Religare Finvest Limited | ₹4 Cr | Open |
| 05 May 2015 | Religare Finvest Limited | ₹1.43 Cr | Open |
| 06 Feb 2015 | Religare Finvest Limited | ₹2.92 Cr | Open |
| 05 Sep 2014 | Religare Finvest Limited | ₹20.65 Cr | Open |
Total charge records: 13 View all charges
Legal Cases of Stellence Pharmscience Private Limited
Stellence Pharmscience Private Limited has 23 court cases on record: 8 filed by Stellence Pharmscience, 15 filed against it. 8 cases are pending and 15 are disposed. Status as checked between 21 Sep 2026 and 04 Oct 2026.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 10 | 10 | 2 |
| NCLAT | 7 | 4 | 4 |
| High courts | 6 | 1 | 2 |
Cases on record (5 of 23)
| Court | Type of case | Party | Status |
|---|---|---|---|
| High Court of Karnataka | Writ petition | Filed by the company against Religare Finvest Limited | Pending |
| District court, Mumbai CMM Courts, Maharashtra | Interim or miscellaneous application | Filed against the company by Jeena and Company Private Limited | Pending |
| NCLAT, Chennai | Interim or miscellaneous application | Filed by the company against Religare Finvest Limited | Disposed |
| NCLAT, Chennai | Insolvency matter | Filed by the company against Religare Finvest Limited and 1 other | Disposed |
| District court, Vadodara, Gujarat | Criminal complaint | Filed against the company by Goel Scientific Glass Works Limited | Disposed |
Full case history
All 23 cases with case numbers, court, year-wise trend, opposite parties and decision dates are in the company report.
- Every case with its case number
- Year-wise trend
- Opposite parties
- Decision dates and orders
Verified entity values are shown only after access is granted.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME Payment Delays by Stellence Pharmscience Private Limited
Stellence Pharmscience Private Limited has 7 MSME Form 1 returns on record between 2017 and 2021, listing 28 overdue payments to 8 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 8)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| an individual supplier | •••• | •••• | •••• |
| an individual supplier | •••• | •••• | •••• |
| Peenya Industrial Gases Private Limited | •••• | •••• | •••• |
| an individual supplier | •••• | •••• | •••• |
| Manoj Cargo Carriers | •••• | •••• | •••• |
Full MSME payment history
Every supplier, amount and due date from all 7 MSME Form 1 returns is in the company report.
- Every reported supplier due
- Amounts and due dates
- Reasons given in each return
- Period-by-period history
Verified entity values are shown only after access is granted.
Individuals and sole proprietors among the suppliers are not named. Amounts, due dates and filing dates are in the company report.
Associated Brands with Stellence Pharmscience Private Limited
Stellence Pharmscience operates two associated brands: STELLENCE PHARMSCIENCE and Avigna Pharmaceuticals. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| An R&D-focused company specializing in manufacturing drugs for various therapeutic areas. | stellencepharmscience.com | |
| Avigna Pharmaceuticals develops and manufactures APIs and specialty chemicals as a contract provider. | avignapharma.com |
Employees and EPFO Compliance at Stellence Pharmscience Private Limited
Stellence Pharmscience Private Limited has a workforce of 103 employees as of Apr 06, 2024.
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
Name History of Stellence Pharmscience Private Limited
Stellence Pharmscience has undergone 2 name changes throughout its history. The company was previously known as Karnataka Chemsyn Limited, and Stellence Pharmscience Limited. The current legal name is Stellence Pharmscience Private Limited.
| Company Name | Status |
|---|---|
| Stellence Pharmscience Private Limited | Current |
| Karnataka Chemsyn Limited | Previous |
| Stellence Pharmscience Limited | Previous |
CIN History of Stellence Pharmscience Private Limited
Stellence Pharmscience has one previous CIN (Corporate Identification Number): U85110KA1992PLC012673. The current CIN is U85110KA1992PTC012673, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U85110KA1992PTC012673 | Current |
| U85110KA1992PLC012673 | Previous |
Recent Activity on Stellence Pharmscience Private Limited
Stellence Pharmscience Private Limited has 13 board changes on record since 2006: 5 appointments and 8 cessations. The latest: Naveen Kumar Jain was appointed as Irp/Rp/Liquidator on 16 Jul 2024.
26 earlier events are listed in the company report.
Credit Ratings, Litigation & Regulatory Alerts for Stellence Pharmscience Private Limited
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Stellence Pharmscience Private Limited
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Stellence Pharmscience Private Limited
Stellence Pharmscience has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 29AABCK9903A1ZP | Karnataka | Active | 01 Jul 2017 |
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Stellence Pharmscience Private Limited
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Stellence Pharmscience Private Limited
Stellence Pharmscience is undergoing "Corporate Insolvency Resolution Process" (CIRP) under the Insolvency and Bankruptcy Code, 2016. Management control has been transferred to an insolvency resolution professional. The company may not be able to independently enter into new commitments during this period. This is a high-risk status - verify the resolution status before any engagement.
Stellence Pharmscience is a company under insolvency, formerly operating as a private limited company based in Bangalore, Karnataka, India. The company works in api manufacturers, within the pharma industry. It was incorporated on 01 January 1992 and is registered under CIN U85110KA1992PTC012673. Caution is advised - the company may not have the legal capacity to fulfil new agreements.
Stellence Pharmscience reported revenue of ₹29.16 Cr for FY 2022 (down 16% YoY).
Stellence Pharmscience has 5 current directors:
- Ramachandran Radhakrishnan - Managing Director
- Anuradha Ramachandran - Director
- Akash Mathur - Director
- Lalit Kumar Yadav - Director
- Naveen Kumar Jain - Irp/Rp/Liquidator
Stellence Pharmscience reported a net loss of ₹5.88 Cr (net margin -20.2%) and EBITDA of ₹4.48 Cr (EBITDA margin 15.4%) for FY 2022, as per its filed financial statements.
The compounded annual growth rate (CAGR) of the revenue of Stellence Pharmscience is 23% over three years and -8% over five years. In the latest year (FY 2022) revenue fell 16%. CAGR is the steady yearly rate that links the first and the last year.
The CIN (Corporate Identification Number) of Stellence Pharmscience is U85110KA1992PTC012673. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Stellence Pharmscience has open charges of ₹38 Cr and satisfied charges of ₹31.92 Cr as per latest MCA filings.
Stellence Pharmscience has 23 court cases on record: 8 filed by the company and 15 filed against it. 8 are pending. Most are in the district courts.
Stellence Pharmscience was incorporated on 01 January 1992. It is registered with the Registrar of Companies, Bangalore.
The peers of Stellence Pharmscience by revenue are Magnum Chemi-Gran Private Limited, Mahrshee Organics Private Limited, Admiron Life Sciences Private Limited, G.M. Chemie Private Limited, Trimax Bio Sciences Private Limited and 5 more, all in the Pharma industry (API Manufacturers).
Naveen Kumar Jain was appointed as Irp/Rp/Liquidator on 16 Jul 2024. Akash Mathur ceased to be Additional Director on 30 Sep 2020. Lalit Kumar Yadav ceased to be Additional Director on 30 Sep 2020. Stellence Pharmscience has 13 board changes on record in total.